Key Highlights

  • Gilead's 2026 reported EPS guidance shows a loss purely because of about $11.5 billion in acquired IPR&D charges from three acquisitions; underlying product sales guidance was raised to $30.0–$30.4 billion.
  • The October 2025 Patent settlements pushing US generic Biktarvy to April 2036 buy the HIV Franchise several extra years, materially changing the cliff maths versus the previously assumed 2033.
  • Yeztugo's launch is the swing Factor : coverage is now broad, but volumes and the unresolved USPSTF question are what drove Leerink's 2031 PrEP estimate down by a third.
  • Gilead Sciences enters August with the densest regulatory calendar it has faced in years and a share price well below its 2026 peak.

A pullback into a crowded catalyst window

Gilead Sciences ( Nasdaq :GILD) enters August with the densest regulatory calendar it has faced in years and a share price well below its 2026 peak. The FDA's target action date for bictegravir plus lenacapavir, a once-daily single-tablet regimen for adults already virologically suppressed, is, following the priority review granted in April. Second-quarter results land three weeks earlier, on 4 August.

What has changed since the spring is sentiment, not the calendar. On 20 July, Leerink Partners cut Gilead to Market Perform from Outperform and trimmed its target to $127 from $146, citing difficulties in the HIV prophylaxis market and lowering its 2031 forecast for the pre-exposure prophylaxis (PrEP) portfolio to roughly $4 billion from $6 billion. Two weeks earlier HSBC moved the other way, upgrading to Buy with a $155 target on the argument that consensus assumes too steep a decline in HIV once older regimens lose protection. The disagreement is the story.

Where the stock actually stands

Gilead closed at $130.21, down 0.82% on the day, giving a market Capitalization of about $161.7 billion. That is roughly 15% below the 2026 high of $153.91 and short of the $157.29 reached within the past 52 weeks, yet still up about 7% from the 2025 close of $121.25 and around 13% over 12 months. The shares sit close to both their 50-day and 200-day moving averages, near $129.74 and $131.77.

After gains of 36.6% in 2025 and 18.7% in 2024, the 2026 drift looks less like a rejection of the Business than a pause, compounded by genuine debate over how quickly injectable prevention scales.

The franchise that pays for everything

HIV medicines generate roughly two-thirds of Gilead's Revenue , and that concentration is both the strength and the vulnerability. In the first quarter of 2026 the HIV portfolio produced $5.0 billion of sales, up 10% year on year, with Biktarvy contributing $3.4 billion (up 7%) and Descovy $807 million (up 38%). Descovy's jump reflects PrEP Demand rather than treatment use; Gilead reported record US PrEP share above 45% for the product during 2025.

The answer to eventual generic competition is a run of long-acting launches. Yeztugo, the twice-yearly lenacapavir injection approved in June 2025 for HIV prevention, booked $166 million in the first quarter against guidance of about $800 million for the year. Gilead also settled with Lupin, Cipla and Laurus Labs in October 2025, pushing US generic Biktarvy entry to April 2036, years later than the 2033 cliff investors had penciled in.

First-quarter numbers, and a guidance line that needs explaining

Total first-quarter revenue was $7.0 billion, up 4%, with product sales excluding the COVID antiviral Veklury up 8%. Non-GAAP Operating Margin expanded to 46.9% from 43.4%, and non-GAAP Diluted Earnings per Share reached $2.03 against $1.81 a year earlier. Free Cash Flow was $2.4 billion; Gilead paid $1.0 billion in dividends, repurchased $419 million of stock and repaid $2.8 billion of Debt , ending March with $8.6 billion of cash.

The headline guidance looks alarming and is not what it appears. Gilead raised 2026 product sales guidance to $30.0–$30.4 billion but simultaneously guided to a non-GAAP diluted loss of $0.65–$1.05 per share, down from $8.45–$8.85 previously. The swing is entirely the roughly $11.5 billion of acquired in-process R&D charges from the Arcellx, Ouro Medicines and Tubulis deals, Acquisition accounting, not deterioration in the underlying business. Third-party research' consensus for the 4 August report is a loss of $7.07 per share on revenue of about $7.37 billion, for the same reason.

Oncology: the expensive second leg

Gilead spent roughly $16 billion across three transactions in early 2026. The largest, Arcellx at $7.8 billion in Equity value plus a contingent value right, brought anito-cel, a BCMA-directed CAR-T with a US decision expected in December 2026 in fourth-line-plus multiple myeloma.

The existing base is mixed. First-quarter oncology sales of $810 million grew 7%, but the composition was uneven: Trodelvy rose 37% to $402 million while Yescarta fell 14% to $332 million and Tecartus slipped 4%. Trodelvy's trajectory improved in June, when the FDA approved it as monotherapy for first-line metastatic triple-negative breast cancer in patients ineligible for PD-(L)1 therapy, and with pembrolizumab in PD-L1-positive disease. The approvals rest on ASCENT-03 and ASCENT-04, which showed 38% and 35% reductions in the risk of progression or death respectively.

Why the long-acting bet could work

The optimistic case rests on duration. If BIC/LEN is approved on 27 August, Gilead can begin migrating Biktarvy patients onto a regimen with a far longer patent runway, blunting the 2036 cliff before it arrives. Behind it sit once-weekly oral islatravir/lenacapavir, which met its primary endpoint in both ISLEND-1 and ISLEND-2 in June with non-inferiority to Biktarvy and to standard care, and once-weekly oral lenacapavir for prevention, under review with a action date. Payer resistance has eased too: CVS Caremark reversed its Yeztugo exclusion effective recently, and Gilead says more than 85% of US insurers now cover it.

What the skeptics are pricing in

The doubters have real evidence. Yeztugo's launch, while covered, has not been explosive, $166 million in a quarter against a roughly $30,000 annual list price implies modest Volume , and the US Preventive Services Task Force has not updated its PrEP guidance to name lenacapavir, leaving zero-cost-sharing status under the Affordable Care Act ambiguous. Leerink's estimate cut targets exactly this. Meanwhile Yescarta is shrinking, cell therapy has proved harder than expected, and $16 billion has just gone into Assets that will not generate revenue for years.

Valuation

Gilead trades on a trailing P/E of about 17.7, price-to-sales near 5.4 and EV/EBITDA around 13.2, with price-to-free-cash-flow of roughly 15.8 on $9.6 billion of trailing free cash flow. A conventional forward P/E is not meaningful this year because reported 2026 EPS guidance is negative on the IPR&D charges; HSBC put the stock near 13 times forward earnings on a normalized basis. The Dividend yields about 2.5% at $3.28 annually, Payout Ratio near 44%. Total debt was roughly $22.2 billion against $9.8 billion of cash. The 29-analyst mean target is $157.15.

Reference points into the autumn

The 4 August release should show whether Yeztugo's run rate supports the $800 million full-year figure, and whether Trodelvy's first-line approval is converting. The August PDUFA is binary and near; December brings anito-cel. Investors weighing Gilead are pricing how much of the next decade's HIV revenue the long-acting portfolio can defend, the accounting noise in 2026 EPS is the least interesting thing on the page.

Upcoming Catalysts

  • Q2 2026 results. Yeztugo and Trodelvy run rates, HIV growth, and any change to the $30.0–$30.4 billion product sales guidance.
  • FDA decision on bictegravir/lenacapavir. Approval would open the Biktarvy switch pathway onto a longer-protected regimen.
  • Anito-cel FDA decision, expected December 2026. The first return on the $7.8 billion Arcellx purchase, in fourth-line-plus multiple myeloma.
  • Once-weekly oral Yeztugo for prevention, PDUFA. A pill alternative for patients unwilling to take injections.
  • Islatravir/lenacapavir regulatory filings. Gilead and Merck said in June they would file the ISLEND data with global regulators.

Principal Risks

  • HIV concentration. Roughly two-thirds of revenue comes from one therapeutic area; any pricing, reimbursement or competitive shock hits disproportionately.
  • PrEP adoption risk. If injectable prevention scales more slowly than guided, the long-acting thesis that justifies the current multiple weakens, as Leerink's downgrade argues.
  • Reimbursement and policy. The USPSTF has not specifically endorsed lenacapavir for PrEP, leaving ACA zero-cost-sharing coverage unsettled; US public-health HIV funding has been volatile.
  • Capital allocation. About $16 billion was committed in early 2026 to assets that are years from revenue, and cell therapy has already disappointed at Yescarta.
  • Oncology competition. Trodelvy faces rival antibody-drug conjugates in breast cancer, and the CAR-T market has repeatedly grown more slowly than forecast.

Conclusion

Gilead's 2026 reported EPS guidance shows a loss purely because of about $11.5 billion in acquired IPR&D charges from three acquisitions; underlying product sales guidance was raised to $30.0–$30.4 billion. Set against that: Roughly two-thirds of revenue comes from one therapeutic area; any pricing, reimbursement or competitive shock hits disproportionately. The next real test: Yeztugo and Trodelvy run rates, HIV growth, and any change to the $30.0–$30.4 billion product sales guidance.

This article is for informational purposes only and does not constitute Investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.